A research team led by Dr. Robert Noble proposes a novel approach to cancer treatment that involves switching therapies while tumors are still shrinking, to outpace the evolution of drug-resistant cancer cells. This strategy could transform cancer care by preventing relapses caused by resistant tumor populations.
- Switching therapies before tumor regrowth may stop resistance early.
- Approach adapts evolutionary models from infectious diseases to cancer.
- Clinical trials are testing this strategy in several cancer types.
What happened
Researchers at St George's, University of London, led by Dr. Robert Noble, studied how tumors develop resistance to cancer treatments and how timing therapy changes could improve outcomes. Using mathematical models adapted from evolutionary biology, they found that switching treatments before a tumor regrows could reduce the chance of resistant cancer cells dominating.
Traditionally, cancer therapies continue until there is visible tumor regrowth, signaling resistance has developed. The new approach suggests applying a second, different treatment while the tumor is still shrinking, effectively 'kicking it while it's down' to keep cancer cells from gaining a foothold with resistant mutations.
Why it feels good
This fresh strategy taps into principles that have successfully managed resistance in other health challenges, like antibiotic resistance and flu vaccine planning. By understanding cancer through an evolutionary lens, doctors may stay ahead of the tumor’s ability to adapt and survive different treatments.
The approach offers hope in cancers prone to treatment failure due to resistance. Early switching could make it harder for any single resistant cancer cell population to dominate, improving chances of long-lasting remission and potentially reducing the need for more aggressive treatments later.
What to enjoy or watch next
While these findings currently come from mathematical modeling, ongoing clinical trials in soft-tissue cancer, prostate cancer, and breast cancer are testing early treatment switching to confirm its benefits in patients. The results from these trials will be critical in determining if this strategy can reshape cancer therapy.
Researchers are also exploring whether switching among three or more therapies in sequence might further improve outcomes, especially in larger tumors. The evolving field promises exciting developments, encouraging patients and clinicians alike to stay informed about the latest advances in combating treatment resistance.